Zyris Nasal Spray contains Xylometazoline (0.1% w/v), a topical nasal decongestant indicated for the relief of nasal congestion associated with conditions such as allergic rhinitis, sinusitis, and the common cold. Xylometazoline acts as an alpha-adrenergic agonist, producing vasoconstriction of the nasal mucosal blood vessels, thereby reducing swelling and facilitating improved nasal airflow. The onset of action is typically rapid, providing symptomatic relief within minutes, and effects may last up to 10 hours. Zyris Nasal Spray is intended for short-term use, generally not exceeding 7 consecutive days, to minimize the risk of rebound congestion or rhinitis medicamentosa. It is contraindicated in patients with hypersensitivity to xylometazoline or any formulation components, and caution is advised in individuals with hypertension, cardiovascular disease, hyperthyroidism, or diabetes. Adverse effects may include nasal dryness, irritation, sneezing, or transient burning sensation. Overuse or prolonged application can lead to mucosal damage and worsening congestion. Zyris Nasal Spray should be used strictly as directed, with appropriate dosing intervals to ensure safety and efficacy. Patients are advised to consult healthcare professionals if symptoms persist beyond one week or worsen.